Fibrobiologics Inc（FBLG）財務資料FBLGFibrobiologics Inc

Evaluating the bottom line, Fibrobiologics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -660.08%, provide a clear picture of how effectively FBLG converts its operational activities into shareholder value.

In the context of the broader market, FBLG competes directly with industry leaders such as ENSC and XCUR. With a market capitalization of $6.87M, it holds a leading position in the sector. When comparing efficiency, FBLG's gross margin of N/A stands against ENSC's 100.00% and XCUR's N/A. Such benchmarking helps identify whether Fibrobiologics Inc is trading at a premium or discount relative to its financial performance.

Fibrobiologics has been facing significant financial challenges, with a net income loss of -5,000,000 USD in Q1 2026 and a gross profit of 0 USD in Q4 2024. The company has a high debt-to-equity ratio of 335.21% in Q4 2024, indicating financial leverage that could pose risks.